Filing Details

Accession Number:
0001439222-24-000014
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-24 16:20:32
Reporting Period:
2024-01-20
Accepted Time:
2024-01-24 16:20:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1439222 Agios Pharmaceuticals Inc. AGIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1546216 Brian Goff C/O Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge MA 02139
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-20 17,018 $0.00 57,071 No 4 M Direct
Common Stock Disposition 2024-01-24 7,635 $21.64 49,436 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance share units Disposition 2024-01-20 17,018 $0.00 17,018 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
102,110 No 4 M Direct
Footnotes
  1. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022.
  2. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
  3. The PSUs were granted on August 8, 2022. The PSUs vest as to 10% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs as to 10% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.